Merus (NASDAQ:MRUS) Receives Buy Rating from Guggenheim

Guggenheim reissued their buy rating on shares of Merus (NASDAQ:MRUS) in a research report released on Wednesday,Benzinga reports.

Several other equities analysts have also recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $85.00 price objective on shares of Merus in a report on Monday, December 9th. HC Wainwright restated a “buy” rating and issued a $85.00 price target on shares of Merus in a research note on Monday, December 2nd. The Goldman Sachs Group initiated coverage on Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective on the stock. UBS Group began coverage on Merus in a report on Thursday, October 24th. They issued a “buy” rating and a $72.00 price objective for the company. Finally, Wells Fargo & Company initiated coverage on shares of Merus in a report on Friday, February 7th. They set an “overweight” rating and a $91.00 target price on the stock. One investment analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $86.08.

Merus Stock Performance

Shares of MRUS opened at $40.26 on Wednesday. Merus has a 12 month low of $37.77 and a 12 month high of $61.61. The firm has a fifty day simple moving average of $41.71 and a 200 day simple moving average of $47.37.

Institutional Investors Weigh In On Merus

A number of institutional investors have recently made changes to their positions in the company. FMR LLC increased its stake in shares of Merus by 10.4% during the third quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company’s stock worth $343,421,000 after purchasing an additional 648,994 shares during the period. Wellington Management Group LLP grew its holdings in Merus by 21.1% in the 4th quarter. Wellington Management Group LLP now owns 3,497,653 shares of the biotechnology company’s stock valued at $147,076,000 after buying an additional 610,139 shares in the last quarter. Franklin Resources Inc. increased its position in Merus by 7.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,256,504 shares of the biotechnology company’s stock worth $117,722,000 after buying an additional 150,341 shares during the period. Holocene Advisors LP lifted its holdings in shares of Merus by 4.1% during the third quarter. Holocene Advisors LP now owns 1,637,988 shares of the biotechnology company’s stock worth $81,834,000 after buying an additional 64,122 shares in the last quarter. Finally, Pictet Asset Management Holding SA boosted its position in shares of Merus by 1.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,031,827 shares of the biotechnology company’s stock valued at $43,388,000 after acquiring an additional 19,379 shares during the period. Institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.